Lexicon Pharmaceuticals | LXRX - Current Liabilities


Lexicon Pharmaceuticals reported $9.9M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Akebia Therapeutics USD 160.86M 13.02M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Halozyme Therapeutics USD 344.44M 18.77M Jun/2026
Illumina USD 1.58B 12M Jun/2026
Insmed USD 438.74M 77.74M Jun/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
J&J USD 55.46B 562M Sep/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
MacroGenics USD 108.82M 12.88M Jun/2026
MannKind USD 142.9M 8.34M Jun/2026
Merck USD 27.73B 786M Jun/2026
Moderna USD 2.53B 139M Jun/2026
Novartis USD 31.75B 374M Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Thermo Fisher Scientific USD 14.17B 899M Sep/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
United Therapeutics USD 607.8M 8.7M Jun/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025